UFIS-SWE-IG
0.1.0 - ci-build

UFIS-SWE-IG, published by UNICOM. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/ufis-swe-ig/ and changes regularly. See the Directory of published versions

Example Bundle: Yasminelle28-tablet-SE-AJ-MPD-BBDL

Yasminelle 28 0,02 mg/3 mg Filmdragerad tablett

MPID: SE-100004813-00023086
EURDID: 10217

Full name: Yasminelle 28 0,02 mg/3 mg Filmdragerad tablett

- Invented Name Part: Yasminelle 28

- Strength part: 0,02 mg/3 mg

- Pharmaceutical dose form part: Filmdragerad tablett

Name usage: Swedish (Kingdom of Sweden)

Authorised dose form: Film-coated tablet

Legal status of supply: Medicinal product subject to medical prescription

Domain: Human use

Resource status: Current

Product classification:

  • 100000095785 drospirenone and ethinylestradiol

Marketing Authorisation 1 of 1

Authorisation number: 23086

Region: Kingdom of Sweden

Marketing authorisation holder: Bayer AB

Identifier:

  • LOC-100016468

Status: Valid (2006-07-21)

Package 1 of 1

PCID:

Description:
Blister, 3 x 28 tabletter

Marketing status:

  • Kingdom of Sweden: Marketed

Pack size:

  • 84 tablet

Package: 1 Box (Cardboard)

Containing:

Package: 3 Blister (Aluminium) (PolyVinyl Chloride)

Containing: 21 tablet

Manufactured Item

Dose form: Film-coated tablet

Unit of presentation: tablet

Ingredient

Role: Active

Substance: Ethinylestradiol betadex clathrate

Presentation strength: 173.17 microgram(s) / 1 tablet

Reference strength:
Ethinylestradiol 20 microgram(s) / 1 tablet

Ingredient

Role: Active

Substance: drospirenone

Presentation strength: 3 milligram(s) / 1 tablet

Reference strength:
drospirenone 3 milligram(s) / 1 tablet

7 tablet